A new article from NCI suggests that HDAC inhibitors vorinostat and romidepsin could potentially benefit synovial sarcoma patients:
Yet only one clinical trial is recruiting sarcoma patients for vorinostat (in combination with another drug):
And other trials that started several years ago have presently an unknown status:
This is not the first time that HDAC is designated as a good target for synovial sarcoma and in the past, other HDAC inhibitors trials have been listed in the clinical trial database, yet all seem to end up in the "unknown status" eventually with no result, either bad or good. I am wondering what's going on behind the doors...